TY - JOUR AU - Naghmeh Niktoreh, AU - Beate Lerius, AU - Martin Zimmermann, AU - Bernd Gruhn, AU - Gabriele Escherich, AU - Jean-Pierre Bourquin, AU - Michael Dworzak, AU - Lucie Sramkova, AU - Claudia Rossig, AU - Ursula Creutzig, AU - Dirk Reinhardt, AU - Mareike Rasche, PY - 2018/12/31 Y2 - 2024/03/29 TI - Gemtuzumab ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report by Berlin-Frankfurt-Münster study group JF - Haematologica JA - haematol VL - 104 IS - 1 SE - Articles DO - 10.3324/haematol.2018.191841 UR - https://haematologica.org/article/view/8728 SP - 120-127 AB - Despite intensified salvage treatments, children with relapsed/refractory acute myeloid leukemia (AML) have poor survival. We evaluated gemtuzumab ozogamicin (CD33-targeted drug) used on a compassionate basis in patients diagnosed from 1995 until 2014 within Acute Myeloid Leukemia Berlin-Frankfurt-Münster studies, and identified 76 patients (